Review of the current targeted therapies for non-small-cell lung cancer

Table 1 Selected current targeted therapies for non-small cell lung cancer and their stages of development

Drug	Company	Stage of development in NSCLC
EGFR activating mutations
Gefitinib	AstraZeneca	Approved
Erlotinib	Roche	Approved
Afatinib	Boehringer Ingelheim	Approved
Dacomitinib	Pfizer	Phase III
CO-1686	Clovis	Phase I/II
AZD9291	AstraZeneca	Phase I/II
ALK gene rearrangements
Crizotinib	Pfizer	Approved
LDK378	Novartis	Phase III
AP26113	ARIAD	Phase II
Alectinib	Chugai	Phase II
X-396	Xcovery	Phase I
PF-06463922	Pfizer	Phase I
ROS1 gene rearrangements
Crizotinib	Pfizer	Phase II (approved for ALK-positive NSCLC)
LDK378	Novartis	Phase II
PF-06463922	Pfizer	Phase I
HER2 activating mutations
Trastuzumab	Genentech	Phase II
Afatinib	Boehringer Ingelheim	No HER2-mutant NSCLC specific trial
Neratinib	Puma Biotechnology	Phase II
BRAF activating mutations
Dabrafenib	GlaxoSmithKline	Phase II

NSCLC: Non-small-cell lung cancer; ALK: Anaplastic lymphoma kinase.